Sculptra® 2 (poly-L-lactic acid, PLLA) is a non-immediate injectable biostimulator that promotes collagen production to gradually restore facial volume and improve skin quality. Proper Sculptra 2 reconstitution is critical to ensure clinical efficacy, minimize complications such as nodules, and achieve uniform distribution of the product.

This guide is intended exclusively for licensed medical professionals and summarizes current recommendations based on evidence and clinical experience to safely and effectively prepare and inject Sculptra® 2. We also address anatomical considerations, patient selection, differences from other biostimulators, and comparative technique tables.

---

1. Composition of Sculptra® 2

• Active ingredient: Lyophilized poly-L-lactic acid (PLLA)
• Format: 150 mg sterile powder vial for reconstitution
• Manufacturer: Galderma
• Mechanism: Stimulates fibroblasts to produce type I and III collagen

Sculptra® contains no hyaluronic acid. Its effect is gradual rather than immediate: results begin to appear after 4–6 weeks and continue improving over several months.

---

2. Recommended Dilution: How Much Solution to Use?

A. Standard reconstitution (facial use):

• Total dilution volume: 5–8 mL of sterile water for injection (WFI)
• Hydration time: ideally 12 to 24 hours before use
• Suggested formula: 6 mL WFI + 1 mL of 1% lidocaine

B. Hyperdiluted reconstitution (body use):

• Total volume: up to 10 mL or more (depending on treatment area)
• Examples: glutes, abdomen, arms, thighs

C. Reconstitution Table by Area

Treatment Area	Total Volume per Vial	Dilution Type	Clinical Indications
Full face	7 mL	standard	Volume loss, facial contour improvement
Temples	6–7 mL	standard	Hollowing, upper facial contour
Neck	8–10 mL	hyperdiluted	Fine lines, mild laxity
Glutes	10–12 mL	hyperdiluted	Volume enhancement, non-surgical BBL
Abdomen	8–10 mL	hyperdiluted	Skin tightening, texture improvement

---

3. Required Materials

• 1 vial of Sculptra® 2
• Sterile water for injection (WFI)
• 1% lidocaine without epinephrine (optional)
• 18G spinal needle or sterile transfer system
• 10 mL Luer-Lock syringes
• 25G/27G cannulas or 25G hypodermic needles
• Vortex or manual shaker
• Sterile field setup

---

4. Step-by-Step Reconstitution Protocol

1. Disinfect vial stopper with 70% isopropyl alcohol.
2. Withdraw 7 mL of sterile WFI into syringe.
3. Inject slowly into the vial, directing against the interior vial wall (avoid forceful shaking).
4. Let hydrate for a minimum of 12 hours (preferably 24) at room temperature (15–30 °C).
5. Gently agitate before use until fully dissolved and particle-free.
6. Optional: add 1 mL of lidocaine just before injection.
7. Transfer solution into sterile treatment syringes.

---

5. Ideal Patient Selection

Criteria	Positive Indicators
Age	30–60 years, progressive volume loss
Skin quality	Mild-to-moderate laxity, thin skin
Treatment goals	Natural, gradual improvement
Post-bariatric patients	Excellent for body contouring
Preference	Avoid immediate volumizers like HA fillers

Sculptra® is contraindicated in patients with autoimmune diseases, active infection, pregnancy, or those under immunosuppressive therapy.

---

6. Recommended Injection Technique

• Injection plane: supraperiosteal or deep subdermal
• Suggested tools:
  • 25G x 50 mm cannula for facial use
  • 27G needle for small/superficial zones
• Techniques:
  • Linear retrograde injection
  • Fanning technique
  • Microbolus for precision areas

Approximate Doses by Facial Zone (per session):

Area	Volume per Side	Recommended Technique
Cheeks	1.5–2 mL	Fanning with cannula
Temples	0.5–1 mL	Retrograde injection
Jawline	1–1.5 mL	Deep linear retrograde
Marionette lines	0.5–1 mL	Microbolus deposits

---

7. Post-Injection Massage Protocol: The 5-5-5 Rule

• 5 minutes, 5 times per day, for 5 days
• Gently massage treated area using circular motion
• Promotes even product distribution and reduces nodule risk

---

8. Post-Treatment Care and Warnings

• Avoid sun exposure, sauna, and strenuous exercise for 24–48 hours
• Avoid makeup or topical actives for 12 hours
• Inform patients results are not immediate
• Assess need for additional sessions at 6–8 weeks

---

9. Sculptra® vs. Other Biostimulators

Feature	Sculptra® 2	Radiesse®	Ellansé™
Active substance	PLLA	Calcium hydroxylapatite	PCL
Onset of results	4–6 weeks	2–3 weeks	~4 weeks
Average duration	24–30 months	12–18 months	12–36 months
Injection plane	Deep subdermal	Subdermal	Supraperiosteal
Reconstitution needed	Yes	No	No

---

10. Conclusion

Sculptra® 2 (poly-L-lactic acid, PLLA) is a non-immediate injectable biostimulator used in Sculptra 2 reconstitution that promotes collagen production to gradually restore facial volume and improve skin quality. Proper reconstitution is critical to ensure clinical efficacy, minimize complications such as nodules, and achieve uniform distribution of the product.

This guide is intended exclusively for licensed medical professionals and summarizes current recommendations based on evidence and clinical experience to safely and effectively prepare and inject Sculptra® 2. We also address anatomical considerations, patient selection, differences from other biostimulators, and comparative technique tables.

---

References (Official and Peer-Reviewed Sources)

1. Galderma. Sculptra® Aesthetic – Full Prescribing Information. https://www.galderma.com
2. Sundaram H, et al. “Biostimulatory effects of injectable poly-L-lactic acid.” Dermatol Surg. 2020. https://doi.org/10.1097/DSS.0000000000002322
3. U.S. FDA. Sculptra (PLLA) Approval Documents. https://www.accessdata.fda.gov
4. Gniadecka M, et al. “Poly-L-lactic acid: review of safety and efficacy.” J Clin Aesthet Dermatol. 2017.
5. Galderma Training Manual. Sculptra® Reconstitution and Injection Guide for Healthcare Professionals (Internal Document)

---